OncoMatch/Clinical Trials/NCT06748222
E-Mindfulness Approaches for Living After Breast Cancer
Is NCT06748222 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies non-drug interventions for breast cancer.
NRG-CC015 is a prospective, randomized phase III clinical trial to evaluate the efficacy of two distinct digital approaches for delivering a mindfulness-based intervention: a live, instructor-led version delivered over Zoom (MAPs LO), and an app-based, self-paced version (MAPs App). Participants will include younger breast cancer survivors (BCS) who were diagnosed with breast cancer at or before age 50 years, have completed their primary cancer treatment (i.e., surgery, radiation, and/or chemotherapy) at least 6 months earlier, and report elevated depressive symptoms.
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Disease stage
Required: Stage 0, I, II, III
Excluded: Stage IV
first-time diagnosis of non-metastatic breast cancer which is Stage 0, I, II, or III
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Mayo Clinic Hospital in Arizona · Phoenix, Arizona
- Mercy Hospital Fort Smith · Fort Smith, Arkansas
- Kaiser Permanente-Deer Valley Medical Center · Antioch, California
- AIS Cancer Center at San Joaquin Community Hospital · Bakersfield, California
- Marshall Cancer Center · Cameron Park, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify